Upstream Bio to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) announced CEO Rand Sutherland will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston on March 4 (Fireside Chat at 9:50 a.m. ET) and Leerink Partners Global Healthcare Conference in Miami on March 9 (Fireside Chat at 1:40 p.m. ET).
Live webcasts will be available under the Events tab on the Investors section of Upstream Bio’s website, and replays will be posted after the presentations.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
UPB’s -1.25% move contrasts with mixed biotech peers: SYRE -1.63%, RAPP -3.97%, QURE +0.75%, VERV -0.09%, TRML 0%. Only TSHA appeared on the momentum scanner, moving up with no news, suggesting stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Phase 2 VALIANT data | Positive | -47.2% | Positive VALIANT Phase 2 severe asthma data with strong AAER reductions. |
| Feb 10 | VALIANT webcast setup | Positive | +6.5% | Announcement of webcast to present upcoming VALIANT Phase 2 top-line results. |
| Jan 05 | JPM conference presentation | Positive | -3.5% | Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 25 | December conferences | Positive | +10.7% | Participation in two December 2025 healthcare investor conferences with webcasts. |
| Nov 05 | Q3 2025 results | Positive | -4.3% | Q3 2025 financials plus positive Phase 2 VIBRANT results and pipeline progress. |
Positive clinical and business updates have produced mixed reactions, with several major positive data events followed by sharp or moderate declines.
Over the past six months, UPB has reported multiple clinical and corporate milestones. On Nov 5, 2025, Q3 2025 results and strong Phase 2 progress in CRSwNP, severe asthma, and COPD coincided with a -4.27% move. December 2025 investor conference participation saw a 10.67% gain. In early February 2026, anticipation for VALIANT Phase 2 data drove a 6.47% rise, but the positive top-line VALIANT readout on Feb 11, 2026 was followed by a sharp -47.18% decline. Today’s conference announcement fits within this ongoing investor communications cadence.
Market Pulse Summary
This announcement details UPB’s participation in March investor conferences and access to live and replay webcasts. It follows a series of significant updates, including Phase 2 VALIANT and VIBRANT data and Q3 2025 results showing continued development of verekitug. Investors tracking the story may focus on how management frames recent clinical outcomes, cash runway through 2027, and next steps toward Phase 3 in severe asthma and CRSwNP during these fireside chats and presentations.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March:
- TD Cowen 46th Annual Health Care Conference, Boston, MA
Wednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET - 2026 Leerink Partners Global Healthcare Conference, Miami, FL
Monday, March 9, 2026, Fireside Chat - 1:40 p.m. ET
Live webcasts of the presentations will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay of the webcasts will be posted on the Company's website following the presentations.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
When will Upstream Bio (UPB) present at the TD Cowen Health Care Conference in March 2026?
What time is Upstream Bio (UPB) scheduled to speak at the Leerink Partners Global Healthcare Conference?
How can investors watch Upstream Bio (UPB) presentations from the March 2026 conferences?
Will Upstream Bio (UPB) post replays of the March 2026 investor conference webcasts?
Who will represent Upstream Bio (UPB) at the March 2026 investor conferences?
What topics might Upstream Bio (UPB) discuss during the March 2026 fireside chats?
